NuVasive® is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the third largest medical device company in the $8.2 billion global spine market. NuVasive’s principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform’s lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 90 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.
Company Growth (employees)
San Diego, US
Size (employees)
2,200 (est)+38%
NuVasive was founded in 1997 and is headquartered in San Diego, US

NuVasive Office Locations

NuVasive has offices in San Diego, Memphis, Columbia, Fairborn and in 9 other locations
San Diego, US
Amstelveen, NL
Milano, IT
Chūō-ku, JP
Elstree, GB
Singapore, SG
Guaynabo, PR
Bremen, DE
Kew, AU
Aliso Viejo, US
Fairborn, US
Columbia, US
Memphis, US

NuVasive Metrics

NuVasive Summary

Market capitalization

$3.8 b

Closing share price

NuVasive's current market capitalization is $3.8 b.

NuVasive Financials

NuVasive's revenue is $962.1 m in FY, 2016
FY, 2013Y, 2014Y, 2015FY, 2016


$685.2 m$762.4 m$811.1 m$962.1 m

Revenue growth, %


Gross profit

$504.7 m

Operating expense total

$471.6 m


($13.6 m)

Net Income

$7 m$35.4 m

Operating cash flow

($20.5 m)

NuVasive Market Value History

NuVasive Online Presence

NuVasive Company Life

You may also be interested in